Teachers Advisors LLC Takes Position in Tocagen Inc (TOCA)
Teachers Advisors LLC bought a new position in shares of Tocagen Inc (NASDAQ:TOCA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,043 shares of the company’s stock, valued at approximately $181,000. Teachers Advisors LLC owned approximately 0.08% of Tocagen as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in shares of Tocagen during the 2nd quarter worth about $4,960,000. Victory Capital Management Inc. acquired a new stake in shares of Tocagen during the 2nd quarter worth about $837,000. Bank of New York Mellon Corp acquired a new stake in shares of Tocagen during the 2nd quarter worth about $281,000. Alps Advisors Inc. acquired a new stake in shares of Tocagen during the 2nd quarter worth about $215,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Tocagen during the 2nd quarter worth about $183,000. 38.25% of the stock is currently owned by institutional investors and hedge funds.
Separately, Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, September 14th.
Tocagen Inc (TOCA) opened at $10.11 on Thursday. Tocagen Inc has a 12-month low of $8.60 and a 12-month high of $17.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. equities analysts anticipate that Tocagen Inc will post -2.88 earnings per share for the current year.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.